Stanford Uses AI to Discover Natural Alternative to Ozempic With Fewer Side Effects
Key Takeaways
- ▸AI algorithm (Peptide Predictor) identified BRP molecule that suppresses appetite and reduces weight similarly to Ozempic but without nausea, constipation, or muscle loss in animal studies
- ▸BRP works through a more targeted approach, acting primarily in the brain's hypothalamus rather than affecting multiple tissues throughout the body like semaglutide
- ▸Peptide Predictor dramatically accelerated discovery by computationally screening all human genes—a process that would have been impractical with traditional wet-lab methods
Summary
Stanford Medicine researchers have used artificial intelligence to identify a naturally occurring molecule called BRP that exhibits weight-loss effects similar to semaglutide (Ozempic), but appears to avoid several common side effects. The discovery was made possible by the Peptide Predictor algorithm, which computationally searched through all 20,000 human protein-coding genes to identify biologically active peptides that might influence appetite and energy balance—a task that would be impossibly time-consuming with traditional laboratory methods.
In animal studies, BRP demonstrated appetite suppression and weight reduction comparable to semaglutide while avoiding nausea, constipation, and significant muscle loss. The key difference is that while semaglutide activates receptors throughout the body—in the brain, gut, pancreas, and other tissues—BRP appears to act specifically in the hypothalamus, the brain region that controls hunger and metabolism. This targeted mechanism could explain why BRP produces fewer off-target effects.
Dr. Katrin Svensson, the senior author of the research published in Nature, has co-founded a company that plans to begin human clinical trials of BRP in the near future. The study was led by senior research scientist Laetitia Coassolo, PhD, and represents a significant validation of AI's potential to accelerate drug discovery in the obesity treatment space.
- Stanford spinout company plans to begin human clinical trials, potentially advancing toward a better-tolerated obesity treatment
Editorial Opinion
This research exemplifies AI's transformative potential in drug discovery, where computational power can systematically identify promising compounds that traditional screening might overlook. The fact that BRP achieves appetite suppression through a more targeted mechanism is a genuine scientific advance, suggesting a path toward more tolerable obesity treatments. However, animal models frequently fail to predict human outcomes, and the upcoming clinical trials will be decisive in determining whether this AI-discovered molecule can deliver on its early promise.
